Volume 131, Issue 15



April 12, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: CCL15 is an important novel diagnostic biomarker for chronic GVHD.  See the article by Du et al.

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
Using an elegant CRISPR/Cas screen of FLT3ITD+ mutant acute myeloid leukemia cells, Gallipoli et al. show in a plenary paper that FLT3 inhibition exposes a therapeutically relevant metabolic dependency on glutaminolysis.

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
The results of this multicenter phase 2 study of the use of venetoclax for patients with chronic lymphocytic leukemia that progresses during or after treatment with idelalisib or ibrutinib reveal a high objective response rate (67%) and an estimated progression-free survival of 79% at 12 months, with only moderate toxicity.

Canonical Notch signaling is dispensable for adult steady-state and stress myelo-erythropoiesis
The effects of Notch signaling in hematopoietic stem and progenitor cells have remained controversial. Duarte and colleagues interfered genetically with the Notch transcriptional complex in hematopoiesis, demonstrating that canonical Notch signals are dispensable in primitive hematopoietic progenitors as well as across the myeloid, erythroid, and megakaryocytic lineages.

Extracellular vesicle–mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling
This paper reports that exosomes and microvesicles produced by lymphoma B cells carrying MyD88L265P reprogram the bone marrow environment by activating endogenous proinflammatory signaling pathways in recipient nonmalignant cells. This study highlights the key role of extracellular vesicles derived from malignant B cells in lymphoma progression.

Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients
This study demonstrates that chemokine (C-C motif) ligand 15 (CCL15) is a diagnostic and prognostic biomarker for chronic graft-versus-host disease (GVHD). Furthermore, antibody inhibition of its homolog, CCL9, reverses established lung GVHD in a mouse model.

Introduction to a review series on Hodgkin lymphoma: change is here
The articles in this series of reviews on Hodgkin lymphoma explore advances in biological insights that have led to the identification of novel targets for drug development and enabled more accurate prognostication. They also examine optimization of various therapeutic strategies for early-stage, advanced-stage, and relapsed disease.

The articles in this review series, "Hodgkin Lymphoma: change is here", include the following:


View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.